These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29431973)

  • 1. OnabotulinumtoxinA Injections for Urge Incontinence.
    Hubb AJ; Stachowicz AM; Wood SC
    Am Fam Physician; 2018 Feb; 97(3):Online. PubMed ID: 29431973
    [No Abstract]   [Full Text] [Related]  

  • 2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on: Anticholinergic therapy vs onabotulinumtoxinA for urgency urinary incontinence.
    Kobashi KC; Patel B
    Urology; 2013 Jul; 82(1):14-5. PubMed ID: 23642706
    [No Abstract]   [Full Text] [Related]  

  • 4. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.
    Lahdes-Vasama TT; Anttila A; Wahl E; Taskinen S
    Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.
    Visco AG; Brubaker L; Richter HE; Nygaard I; Paraiso MF; Menefee SA; Schaffer J; Wei J; Chai T; Janz N; Spino C; Meikle S;
    Contemp Clin Trials; 2012 Jan; 33(1):184-96. PubMed ID: 22008247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticholinergic drugs or botulinum toxin for urge incontinence?
    BMJ; 2012 Oct; 345():e6732. PubMed ID: 23054049
    [No Abstract]   [Full Text] [Related]  

  • 7. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions.
    Madersbacher S
    Eur Urol; 2013 Aug; 64(2):257-9. PubMed ID: 23731721
    [No Abstract]   [Full Text] [Related]  

  • 8. [What to do in cases of inadequate effectiveness of botulinum toxin for the treatment of eyelid cramping?].
    Roggenkämper P
    Ophthalmologe; 2007 Sep; 104(9):763-6. PubMed ID: 17726608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Longitudinal Fluctuations in Treatment Response After OnabotulinumToxinA and Sacral Neuromodulation for Refractory Urgency Incontinence.
    Smits MAC; Heesakkers JPFA
    Eur Urol; 2024 Jun; 85(6):590-591. PubMed ID: 38461141
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply from author re: Stephan Madersbacher. OnabotulinumtoxinA for idiopathic overactive bladder symptoms: many answers but more questions. Eur Urol 2013;64:257-9: OnabotulinumtoxinA for idiopathic overactive bladder symptoms: some answers but even more questions.
    Chapple CR
    Eur Urol; 2013 Nov; 64(5):e100-1. PubMed ID: 23830474
    [No Abstract]   [Full Text] [Related]  

  • 11. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple translucent papules on the face, worsening in summer.
    Wang Y; Li Z; Feng S
    Clin Exp Dermatol; 2020 Aug; 45(6):783-785. PubMed ID: 32410292
    [No Abstract]   [Full Text] [Related]  

  • 13. Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. Onabotulinumtoxina.
    Doggweiler R
    J Urol; 2011 Jun; 185(6):2023-4. PubMed ID: 21496846
    [No Abstract]   [Full Text] [Related]  

  • 14. Uses of botulinum toxin.
    Girdler NM
    Lancet; 1997 Mar; 349(9056):953. PubMed ID: 9093271
    [No Abstract]   [Full Text] [Related]  

  • 15. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).
    Tincello DG; Kenyon S; Abrams KR; Mayne C; Toozs-Hobson P; Taylor D; Slack M
    Eur Urol; 2012 Sep; 62(3):507-14. PubMed ID: 22236796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of mirror dystonia as guidance for injection of botulinum toxin in writing dysfunction.
    Singer C; Papapetropoulos S; Vela L
    J Neurol Neurosurg Psychiatry; 2005 Nov; 76(11):1608-9. PubMed ID: 16227568
    [No Abstract]   [Full Text] [Related]  

  • 17. [Using botulinum toxin (Botox) for treatment of patients with postroke spasticity].
    Khat'kova SE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(6):87-90. PubMed ID: 19685598
    [No Abstract]   [Full Text] [Related]  

  • 18. Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.
    Adler CH; Factor SA; Brin M; Sethi KD
    Mov Disord; 2002 Jan; 17(1):158-61. PubMed ID: 11835455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular injection of botulinum toxin as an adjunct to arthrocentesis of the temporomandibular joint: preliminary observations.
    Freund BJ; Schwartz M
    Br J Oral Maxillofac Surg; 2003 Oct; 41(5):351-2. PubMed ID: 14581034
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment with botulinum toxin in neurologic pediatrics].
    Justus N; Lee SH; Berweck S; Heinen F
    Kinderkrankenschwester; 2007 Jul; 26(7):274-6. PubMed ID: 17726921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.